In Segment A, individuals will get various doses and schedules of oral ABBV-744 tablet to establish Secure dosing routine. More participants is going to be enrolled at the recognized monotherapy dosign routine. In Section B, participants will obtain oral ruxolitinib and ABBV-744 might be offered as "incorporate-on" therapy. In Section https://abbv-744preclinicalstudie57801.blogthisbiz.com/38497335/abbv-744-as-a-potential-therapeutic-option-for-aggressive-cancers-secrets